glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Targeting GLP-1, GIP & GCG

Tirzepatide and cardiovascular disease A previous study has shown that tirzepatide can protect human cardiomyocytes by effectively ameliorating apoptosis, fibrosis, and hypertrophy when exposed to high glucose

This premise is reinforced by the discovery that different immune cells, including B and T lymphocytes, as well as myeloid-lineage cells such as monocytes, eosinophils, and neutrophils, express GLP-1Rs ( 3.1 Innate and adaptive immune response In rat models of systemic inflammation, a GLP-1 RA, exendin, significantly lowered pro-inflammatory cytokine levels, including IL-1, IL-6, TNF-, and interferon-gamma (IFN-) ( in vitro studies, GLP-1 RAs have demonstrated the capacity of promoting an anti-inflammatory state by influencing immune cell differentiation

Type 2 diabetes: They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

The glucagon receptor activation increases energy expenditure through thermogenesis and enhances fat oxidation

A 1 mg starting dose would be 40 units